Opportunities and barriers in omics-based biomarker discovery for steatotic liver diseases

Maja Thiele1,2,†, Ida Falk Villesen1,2,†, Lili Niu1,4, Stine Johansen1, Karolina Sulek2, Suguru Nishijima6, Lore Van Espen7, Marisa Keller3, Mads Israelsen1,2, Tommi Suvitaival5, Andressa de Zawadski2, Helene Baek Juel3, Maximilian Joseph Bro1, Sara Elizabeth Stinson4, Yun Huang8, Maria Camilla Alvarez Silva1, Michael Kuhn4, Ema Anastasiadou10, Diana Julie Leeming11, Morten Karsdal1, Jelle Matthijnssens1, Manimozhiyan Arumugam1, Louise Torp Dalgaard12, Cristina Legido-Quigley5, Matthias Mann1,2,‡, Jonel Trebicka7, Peer Bork6,13,14, Lars Juul Jensen1, Torben Hansen8,⁠‡, Aleksander Krag1,2,* on behalf of MicroLiver consortium, GALAXY consortium

Summary

The rising prevalence of liver diseases related to obesity and excessive use of alcohol is fuelling an increasing demand for accurate biomarkers aimed at community screening, diagnosis of steatohepatitis and significant fibrosis, monitoring, prognostication and prediction of treatment efficacy. Breakthroughs in omics methodologies and the power of bioinformatics have created an excellent opportunity to apply technological advances to clinical needs, for instance in the development of precision biomarkers for personalised medicine. Via omics technologies, biological processes from the genes to circulating protein, as well as the microbiome – including bacteria, viruses and fungi, can be investigated on an axis. However, there are important barriers to omics-based biomarker discovery and validation, including the use of semi-quantitative measurements from untargeted platforms, which may exhibit high analytical, inter- and intra-individual variance. Standardising methods and the need to validate them across diverse populations presents a challenge, partly due to disease complexity and the dynamic nature of biomarker expression at different disease stages. Lack of validity causes lost opportunities when studies fail to provide the knowledge needed for regulatory approvals, all of which contributes to a delayed translation of these discoveries into clinical practice. While no omics-based biomarkers have matured to clinical implementation, the extent of data generated has enabled the hypothesis-free discovery of a plethora of candidate biomarkers that warrant further validation. To explore the many opportunities of omics technologies, hepatologists need detailed knowledge of commonalities and differences between the various omics layers, and both the barriers to and advantages of these approaches.

© 2024 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Introduction

More than one-third of the adult population have steatotic liver disease either metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-related liver disease (ALD) or a combination thereof (MetALD).1-3 Patients with progressive disease experience high liver-related morbidity, extrahepatic complications and premature all-cause mortality.4,5 There is consequently an urgent need for accurate risk stratification and effective treatments that modify the natural course of disease.5,7 Progression of steatotic liver disease follows a profibrotic path, resulting in pivotal liver-related events that critically affect prognosis. It is consequently important to explore biomarkers that predict precursors of cirrhosis and portal hypertension in the form of significant and advanced fibrosis, as these disease stages predict later liver-related events, including decompensation, acute-on-chronic liver failure, hepatocellular carcinoma, and death.9,10 The performance of existing and future biomarkers depends on their intended context of use and validation (Fig. 1, Table 1).11 General practitioners and hepatologists managing ALD, MetALD and MASLD lack tests for the accurate diagnosis of significant fibrosis (≥F2) and steatohepatitis, for prognosis, monitoring and prediction, and for evaluating the efficacy of interventions.6,12 Traditionally, the diagnostic accuracy of a biomarker is evaluated by the area under the receiver-operating characteristic curve, sensitivity, specificity and predictive values. However, these performance characteristics depend on disease prevalence in the studied population.13 Consequently, future biomarkers need to be tailored to the intended population and tested in cohorts which reflect the appropriate disease prevalence.

Keywords: Non-invasive test; genetics; microbiome; metagenomics; metatranscriptomics; viromics; metabolomics; lipidomics; proteomics.

Received 20 September 2023; received in revised form 16 February 2024; accepted 19 March 2024; available online 28 March 2024
* Corresponding author. Address: Center for Liver Research, Department of Gastroenterology and Hepatology, Odense University Hospital, Odense, Denmark. Tel.: +45 29647719.
E-mail address: Aleksander.Krag@rsyd.dk (A. Krag).
† Shared senior authorship
‡ See the section on The Taormina Workshop on Occult HBV Infection Faculty Members, near the end of the paper.
https://doi.org/10.1016/j.jhep.2024.03.035

Journal of Hepatology, August 2024. vol. 81 | 345–359

Review
Key points

- There is an urgent need for accurate biomarkers in patients with steatotic liver disease, to stage and grade fibrosis and inflammation, for monitoring disease progression and for improving drug development and approval pipelines.
- The rapid development and decreased costs of high-throughput omics technologies in combination with excellent computational power has created a golden opportunity for new types of biomarkers which reflect biological disease processes and can be combined in multiplex systems. Multi-omics may thereby facilitate an era of accurate, personalised diagnostics.
- Heterogeneity in the development and progression of steatotic liver disease may be disentangled by studying the interplay between host genetics, transcriptomics, proteomics, metabolomics and lipidomics on the one hand, and gut microbial, viral and fungal metagenomics and meta-transcriptomics on the other hand.
- Hypothesis-free approaches have revealed the potential of omics technologies for the discovery of liver disease biomarkers and have proposed many more candidate biomarkers than the traditional hypothesis-driven studies. However, few of these omics-based biomarker candidates have been rigorously tested in independent cohorts, and none have been implemented in clinical practice.

This review will explore the advantages and limitations of omics technologies for biomarker discovery across the spectrum of steatotic liver disease. We highlight the state of the art of individual omics technologies: genetics, transcriptomics, proteomics, lipidomics, metabolomics, metagenomics, metatranscriptomics, viromics and mycobiomics. These technologies have been selected from a wider list of currently available omics technologies as they are the most common and represent the promises and obstacles of omics-based biomarkers for clinical hepatology.

Opportunities for omics technologies

Recent years have witnessed the beginning of a new era in biomarker development, thanks to high-throughput omics technologies combined with increasing computational power and the ability to apply artificial intelligence and machine learning methods with routine hardware and software. This major advance allows for hypothesis-free testing of thousands or even millions of analytes. Multi-omics is thereby able to disentangle the complex molecular interplay between host genes, gene transcription, proteins, metabolites and lipids, in addition to interactions between the host and microbiome (consisting of bacteria, viruses and fungi) (Fig. 2), resulting in a multitude of candidate biomarkers. In addition, to enable the accurate separation of patients with progressive liver disease from those with non-progressive disease, researchers have looked to understand disease heterogeneity and pathophysiology through the lens of host-gut-environment interactions. Recent developments and promising biomarker targets from omics technology are highlighted in Table 2.

In the struggle to identify effective anti-fibrotic interventions for MASLD and ALD, omics-based biomarkers that reflect biological fibrotic processes may be used to identify future drug targets, thereby abating the frequent failures of phase III clinical trials. There is a similar search for accurate biomarkers to reduce clinical trial screening failures. Finally, non-invasive biomarkers to replace liver biopsy as the surrogate endpoint would effectively allow for shorter, less costly trials and reduced patient discomfort.

The analysis costs of genetics, transcriptomics, proteomics, lipidomics, metabolomics, metagenomics and metatranscriptomics are decreasing thanks to technological development and an increase in the capacity of high-throughput omics platforms. We therefore expect multi-omics approaches to become increasingly accessible for the clinical management of patients with liver disease over the next decade.

Barriers to omics technologies

Omics-based biomarkers offer more opportunities for discovery than traditional biomarkers, which quantify a low number of analytes, often only one. However, no omics-based biomarker has penetrated from development to implementation. This shortcoming can be attributed to several barriers across different omics technologies, including 1) technological maturity, 2) cost, 3) analytical validity, 4) untargeted coverage and 5) semi-quantitative measurements, which are usually laboratory or instrument specific.

Except for genetics, omics technologies are in their infancy (Fig. 3). This immaturity results in several obvious limitations, most notably that the evidence base remains incomplete. Technological development is moving rapidly from high cost and low throughput to low cost and high throughput. However, finite budgets remain a challenge for the maturation of omics-biomarkers. Current cost pressures create a trade-off between analyte depth and abundance vs. sample throughput and sample size. The limited ability to robustly detect low-abundance analytes generates ‘technological bias’. Omics studies typically aim for great depth to discover low-abundance biomarkers, but this means that investigators cannot afford as many samples, thus risking spurious findings. The high-dimensional nature of omics data also requires extensive computational protocols and processing power, further increasing time usage and costs. However, increasingly higher demands for omics technologies within the healthcare system will lead to the development of routine protocols and market competition, driving costs downward.

Omics measurements can be divided into two analytical methods: non-targeted and targeted. Non-targeted omics takes a hypothesis-free approach to the semi-quantitative analysis of a very large number of molecules, often aided by machine learning and other advanced bioinformatics. Non-targeted omics is consequently highly suited for discovery of new biomarkers. However, this approach faces three major challenges: 1) semi-quantitative measurements are relative and, as such, study specific. Findings are therefore difficult to replicate in external validation. Candidate biomarkers detected by untargeted approaches must therefore be validated using a targeted platform, such as ELISA, for absolute concentrations. 2) Non-targeted measurements are more prone to...
analytical biases such as batch effect and variations related to sample handling and processing. Non-targeted approaches usually require more complex and therefore less standardised bio-informatics pipelines.

The targeted approach uses quantitative assays to measure concentrations of predefined panels of up to a few hundred molecules. Targeted omics can be done, for example, by using calibration curves and spike-in of internal standards to allow for absolute quantification and is well suited to either searching for high-abundance biomarkers or for hypothesis-driven biomarker evaluation. Discovery of novel targets and pathways is especially useful for drug discovery and investigations of disease aetiology; however, its application in routine analysis in the clinic is still being evaluated.

Different omics technologies each have their own set of specific advantages which hold great potential for personalised and precision medicine (Fig. 4; Table 2). Nevertheless, in order to bring omics-based biomarkers into the clinic, the current process involves transforming them into analytically reproducible assays that can be validated across laboratories and cohorts while also meeting regulatory requirements. These requirements can be insurance against hurried, spurious findings but can also limit the speed of discovery and development to validation.

The subsequent sections delineate the technical complexities and biomarker prospects across diverse omics disciplines.

**Genetics**

Genetics is the most widely investigated omics technology, linking single nucleotide polymorphisms (SNPs) to cirrhosis, hepatocellular carcinoma and steatosis, particularly for MASLD and ALD. From family and population-based studies, the heritability of MASLD ranges from 20–70% depending on ethnicity and how MASLD is diagnosed. For the heritability of ALD, studies suggest alcohol use disorder heritability ranges from 30–50% and ALD-related cirrhosis ranges from 21–67%. However, disagreement within the field exists on the proportion of the genetic variance for ALD that is independent of the genetic predisposition to alcohol dependence.

Genotyping of individuals for genome-wide association studies (GWAS) is typically performed using microarrays to measure common variants, due to the higher cost of

**Fig. 1. Intended use of biomarkers and the spectrum bias.** Due to the spectrum effect, diagnostic accuracy for the same biomarker will change when tested in populations with different prevalence of disease. Discrete types of omics allow biomarkers to be tailored to the different contexts of use and different disease spectrums. Plots illustrate variability in sensitivity and specificity, as well as PPV and NPV, with disease prevalence in the studied cohort, derived from Usher-Smith et al. cACLD, compensated advanced chronic liver disease; DC, decompensated cirrhosis; F0 – F2, denotes liver fibrosis stage; NPV, negative predictive value; PPV, positive predictive value.
A prognostic biomarker is used to identify the likelihood of a clinical event in a patient, while predictive biomarkers identify patients who are more likely to experience benefit.\(^{a}\) A higher GRS derived from\(^{a}\) includes\(^{a}\) ABCB4, ABCB11 and ATP8B1 sequencing to improve disease prognostication. Examples\(^{a}\) from ALD and MASLD, using liver biopsies, imaging, elastography, liver enzymes and electronic health records. These efforts have identified risk loci common to ALD and MASLD, including PNPLA3, TM6SF2, GCKR, SERPINA1 and MBOAT7\(^{41-45}\). Novel protective loci include HSD13B17, MTARC1, GPAM and PSD3.\(^{35,45,46}\)

Genetic risk scores (GRS) combining multiple SNPs with genome-wide significance (\(p < 5 \times 10^{-8}\)) can be used for risk prediction and stratification. A higher GRS, including PNPLA3, TM6SF2 and HSD17B13, was shown to confer a 12-fold increased risk of cirrhosis and a 29-fold increased risk of hepatocellular carcinoma in the European population.\(^{47}\) Likewise, a higher GRS derived from PNPLA3, TM6SF2, MBOAT7, GCKR and HSD13B17 was shown to amplify the effect of liver steatosis on the risk of subsequent hepatic events.\(^{48}\) Despite considerable interest, the predictive value of a given GRS over simple biochemical biomarkers has been marginal. Combining PNPLA3, TM6SF2, HSD17B13 and MBOAT7 with metabolic traits slightly increases the area under the curve for diagnosing advanced liver fibrosis, from 0.75 to 0.80 in patients with ALD.\(^{49}\) Regarding the prediction of 10-year cirrhosis risk, the addition of a GRS to the APRI score (aspartate transaminase-to-platelet ratio index) provided little additional prognostic information and only marginally improved the C-index from 0.804 to 0.809 in the UK Biobank.\(^{50}\) This limited impact is likely due to the fact that clinical features from 5 to 10 years before disease onset explain more variance than the few SNPs with small effect sizes identified so far.\(^{51}\) Yet there is promise: a study based on UK Biobank data demonstrated that a GRS improves risk stratification and diagnostic accuracy, particularly in subgroups of individuals with diabetes, obesity or a fatty liver index above 60. This suggests that integrating a GRS with non-invasive clinical markers holds the potential to refine individual risk prediction for severe liver disease, especially in individuals at risk for MASLD.\(^{52}\)

Polygenic scores have achieved greater predictive power than GRS for complex diseases by including hundreds to thousands of SNPs, rather than being restricted to only those that reach genome-wide significance (\(p < 5 \times 10^{-8}\)).\(^{53}\) Polygenic scores developed for liver diseases are still under development and require well-powered GWAS studies, validated in independent study populations of varying ancestries to ensure generalisability.

---

**Table 1. Biomarker indications and clinical use.**

<table>
<thead>
<tr>
<th>Outcome of interest</th>
<th>Diagnostic</th>
<th>Prognostic(^{a})</th>
<th>Monitoring</th>
<th>Prediction(^{a})</th>
<th>Surrogate endpoint</th>
</tr>
</thead>
<tbody>
<tr>
<td>Disease present or not; disease staging</td>
<td>Development of clinical events, mortality</td>
<td>Change in disease severity</td>
<td>Effect of treatment</td>
<td>Substitute for one or more clinical outcomes</td>
<td></td>
</tr>
<tr>
<td>Subclasses of biomarkers</td>
<td>Screening</td>
<td>Susceptibility/risk stratification</td>
<td>Efficacy of intervention; pharmacodynamic response</td>
<td>Safety (adverse events)</td>
<td>Reasonably likely surrogate endpoint</td>
</tr>
<tr>
<td>Measurement timing</td>
<td>Baseline</td>
<td>Baseline</td>
<td>Longitudinal</td>
<td>Baseline, before intervention</td>
<td>Start and end of intervention study</td>
</tr>
<tr>
<td>Clinical characteristic</td>
<td>Reflects true disease state</td>
<td>Reflects patient or disease characteristics</td>
<td>Biomarker changes correlate with changes in extent or status of disease</td>
<td>Reflects patient or disease characteristics</td>
<td>Effect on the surrogate endpoint predicts a clinical benefit</td>
</tr>
<tr>
<td>Statistics used</td>
<td>Discriminative accuracy, sensitivity, specificity, NPV, PPV, calibration curves, goodness of fit, information criterion, odds ratio</td>
<td>C-statistics, hazard ratio, time-dependent receiver operating characteristics curve, Aalen-Johansen or Kaplan-Meier estimator</td>
<td>Correlation coefficients: diagnostic and prognostic accuracy of a biomarker(^{a})</td>
<td>Treatment effect in biomarker positive vs. biomarker negative patients if patient groups have the same prognosis</td>
<td>Correlation coefficients: diagnostic accuracy of a biomarker to detect change; prognostic accuracy of a biomarker</td>
</tr>
<tr>
<td>Examples of omics-based biomarkers</td>
<td>Proteomics for diagnosis of ALD fibrosis, inflammation and steatosis(^{55})</td>
<td>Genetic risk polymorphisms for development of hepatocellular carcinoma in the population(^{a})</td>
<td>Changes in lysosphosphocholines by lipidomics in MASLD during dietary intervention(^{51})</td>
<td>A polygenic score to predict weight loss in response to physical activity(^{38})</td>
<td>No omics markers approved as surrogate endpoints, but single molecules may arise from omics discovery</td>
</tr>
</tbody>
</table>

ALD, alcohol-related liver disease; MASLD, metabolic dysfunction-associated steatotic liver disease; NPV, negative predictive value; PPV, positive predictive value; ROC, receiver-operating characteristic curve.

* A prognostic biomarker is used to identify the likelihood of a clinical event in a patient, while predictive biomarkers identify patients who are more likely to experience beneficial or adverse effects of an intervention.

**Δ means change from baseline.
Transcriptomics

The transcriptome is the sum of all RNA transcripts of a tissue or blood sample, commonly used to examine gene expression. Circulating RNA species include several classes of shorter RNAs, with microRNAs (miRNA) being by far the most studied. miRNAs can be quantified by sequencing or reverse-transcription quantitative PCR (qPCR), using targeted or multiplexed panels. These methods are sensitive, often quantitative, and relatively low in cost. In contrast, sequencing all small RNAs is considerably more expensive but allows for measurement of other RNA types, such as PIWI-interacting RNAs, transfer-RNA fragments, ribosomal and nucleolar RNAs, each of which contains tens to thousands of different species.54,55 Small RNAs in circulation constitute a novel source of MASLD-related biomarker candidates, e.g., miR-122, miR-34a, and miR-193a.56–58 Once a promising RNA biomarker has been identified, the RNA can be detected with high sensitivity and accuracy based on targeted reverse-transcription qPCR or microfluidics-based nano-sensors.

The extracellular RNAs are an especially interesting subtype of circulating miRNAs.59 They are enclosed in vesicles or are protein bound, which protects them from degradation and facilitates their transport, in turn allowing for cell-to-cell paracrine communication or long-distance signalling.60 Liver-derived miRNAs, as extracellular RNA, appear to be important regulators of metabolic disease, particularly MASLD and steatohepatitis.65 Recent studies show that levels of liver-derived miRNAs are modified by weight-loss or insulin-sensitising treatments.67–69

MiRNAs also show promise as biomarkers for ALD, MASLD and steatohepatitis, with miR-34a, which is part of the NIS2+ score, being a notable example.63,64 In addition, both miR-193 and miR-122 plasma levels have been shown to be increased in patients with MASLD who have steatohepatitis and advanced fibrosis.65,66 Liver-specific miR-122 also predicts type 2 diabetes and decreases following weight loss.61,62 Yet, low miR-122 is a marker of poor prognosis in patients with cirrhosis.67 Therefore, it appears that the increase in hepatic miR-122 expression is temporary, from upregulation as steatohepatitis progresses, to a decline in patients with cirrhosis – a similar non-linear pattern is seen for changing body weight. While this naturally limits the potential use of miR-122 as a diagnostic biomarker, it points toward a possible role in causal pathways. It also illustrates the importance of consecutive recruitment and inclusion across the disease spectrum in biomarker research.

Microbiome

The human body is home to a large number of microbes, on all skin and mucous surfaces.68 The vast majority reside in the gut, which is home to ten trillion bacteria.69 The gut microbiota exerts important effects on host physiology by producing diverse metabolites, modulating the immune system and preventing infection by pathogens.70 The gut microbiota can profoundly affect the liver, as microbial products can enter the blood circulation and thereby encounter the liver as the very first organ.71–73

Shotgun metagenomic sequencing evaluates both the species-level taxonomic profile and the functional profile of the microbiome but requires resource-heavy sequencing equipment and advanced bioinformatics. The cheaper amplicon sequencing of the bacterial 16 S ribosomal RNA genes enables determination of a taxonomic profile without large computational resources, but with lower resolution, at the genus or family level. Metatranscriptomics quantifies microbial RNA to describe how gene transcriptional activity across bacterial species can change according to health or disease.73

Several studies have shown alterations in the gut microbiome of patients with cirrhosis or steatohepatitis related to...
<table>
<thead>
<tr>
<th>Specimen</th>
<th>Outcomes of interest</th>
<th>Technology (untargeted)</th>
<th>Technology (targeted)</th>
<th>Number of analytes (targeted tech.)</th>
<th>Examples of biomarker candidates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genetics</td>
<td>Whole blood, buffy coat</td>
<td>Whole genome sequencing</td>
<td>Microarray-based genotyping or whole exome sequencing</td>
<td>&gt;6 × 10^6 common SNPs (MAF &gt;0.01)</td>
<td>PNPLA3, TM6SF2, GCKR, MBOAT7, HSD17B13, SERPINA1, PNPLA3, TM6SF2, GCKR, MBOAT7, HSD17B13, SERPINA1</td>
</tr>
<tr>
<td>Transcriptomics</td>
<td>All tissue types, plasma, serum, whole blood</td>
<td>RNA sequences: non-coding RNA (miRNA, long noncoding RNA), coding mRNA, steady state RNA levels</td>
<td>Reverse transcription-quantitative PCR or small RNA-sequencing</td>
<td>10^5</td>
<td>miR-34a, miR-122, miR-21</td>
</tr>
<tr>
<td>Proteomics</td>
<td>All tissue types and body fluids</td>
<td>Protein abundance</td>
<td>Mass spectrometry, Proximity Extension Assay (commercialized by Olink Explore) and SomaScan Assay (commercialized by SomaLogic)</td>
<td>1 - 10^4</td>
<td>TREM-2 was discovered by single-cell sequencing, subsequently developed into an ELISA assay. Complement component C7 identified as a fibrosis marker in two independent biomarker studies.</td>
</tr>
<tr>
<td>Metabolomics and lipidomics</td>
<td>Plasma, urine, stool, liver, adipose tissue</td>
<td>Metabolite abundance. Lipid abundance w.r.t. lipid class, lipid saturation/unsaturation, lipid size</td>
<td>Gas or liquid chromatography coupled to mass-spectrometry</td>
<td>10^5 -10^3</td>
<td>Glutamate and glutamine, Triglycerides, such as TG(48:0), Triglycerides, such as TG(50:2), Phosphatidylcholines, such as PC(36:4), Sphingomyelins, such as SM(41:1), The Metabolomics-Advanced steatohepatitis fibrosis score developed to detect at-risk MASH</td>
</tr>
<tr>
<td>Viromics</td>
<td>Stool, saliva, plasma, skin</td>
<td>Viral genomes (DNA or RNA) and their encoded genes</td>
<td>Shotgun metagenomic sequencing</td>
<td>Variable (depending on sequencing depth and sample diversity) with limited overlap between samples</td>
<td>None, but bacteriophages which target cytolytic Enterococcus faecalis could potentially be markers of resistance against alcohol-induced liver injury.</td>
</tr>
<tr>
<td>Microbiomics</td>
<td>Stool, saliva, skin, mucosa</td>
<td>Bacteriomics</td>
<td>Shotgun metagenomics or amplicon sequencing</td>
<td>100-1,000 species per sample, with 10^6 -10^10 genes</td>
<td>Cytolytic Enterococcus faecalis</td>
</tr>
</tbody>
</table>

GRS, genetic risk scores; MAF, minor allele frequency; MASH, metabolic dysfunction-associated steatohepatitis; SNP, single nucleotide polymorphisms; miRNA, microRNA; NMR, nuclear magnetic resonance.
ALD or MASLD, compared to healthy individuals.74–77 The more severe stages of liver disease are associated with dysbiosis, decreased abundance of potentially beneficial families such as Ruminococcaceae and Lachnospiraceae, and an increase in potentially pathogenic families such as Enterobacteriaceae and Bacteroidaceae.75,76 One metagenomic study in patients with decompensated cirrhosis found elevated levels of Veillonella and Streptococcus species, but reduced levels of butyrate-producing commensal bacteria, including Faecalibacterium prausnitzii and Coprococcus comes.77 Other studies have demonstrated increased epithelial permeability in patients with liver disease, which would allow for translocation of bacterial components and metabolites, such as lipopolysaccharides, secondary bile acids and pathogen-associated molecular patterns, fuelling liver inflammation and fibrosis.78–80 Consequently, microbial products can be important biomarkers of treatment effects, as in the RIFSYS trial, where circulating microbial components and metabolites, such as lipopolysaccharides, secondary bile acids and pathogen-associated molecular patterns, were found in patients with cirrhosis treated with rifaximin-α but increased in placebo-treated patients.81

While accumulating evidence indicates that microbial disturbances play a role in the development and progression of liver diseases, the study of gut microbiota and their potential as biomarkers remains in its infancy.84,85

Viromics and mycobiotics

The virome and myco-biome, though considered premature omics fields, exhibit promise in light of advancing technologies, making them interesting for future exploration.

The gut virome mainly consists of bacteriophages (viruses infecting bacteria) and viruses infecting eukaryotic cells. Viruses are the most diverse genetic elements on earth, which poses several technical challenges for virome research.86

Due to the small genome size of viruses compared to prokaryotes and eukaryotes, the enrichment of faecal samples for viruses before DNA and RNA extraction is recommended. A reverse transcription step is also necessary to capture RNA viruses. As bacteriophages are highly diverse and highly individual specific, they are not sufficiently represented in databases. Hence, a de novo genome assembly approach and a viral identification method that is, at least partially, independent of databases is crucial to identify novel viruses from sequencing data.87

Recent developments in bioinformatics tools have allowed for improved identification (geNomad), taxonomic classification (vConTACT2), host prediction (iPhoP) and functional annotation (Cenote-Taker2) of viral sequences, advancing the field to help identify associations between the virome and human...
Viruses can directly affect the human host by killing target cells such as hepatocytes or by modulating the immune system. The human host can also be indirectly affected by the gut virome through the effect of gut phages on the composition and function of the gut bacterial community. Changes in the gut virome have been linked to the presence and severity of liver diseases, such as MASLD, ALD, alcohol-related hepatitis and cirrhosis. However, the high inter-individual variability of the human gut virome limits the identification of robust viral biomarkers. Overall, viral diversity might be a better biomarker than a set of individual viruses, but viral diversity lacks disease specificity, as seen with dysbiosis. Other approaches which overcome the low prevalence of individual viral genomes are to look for virome biomarkers of higher taxonomical orders (e.g. families) or to group bacteriophages by their bacterial host, but these more diverse groups of viruses will be more difficult to detect using qPCR tests. Finally, virally encoded genes might be less individual specific, for example, toxins or auxiliary metabolic genes, and hence better suited as biomarkers. These genes could be horizontally transferred to their bacterial hosts, thus altering the functional capacities of the targeted bacteria and thereby indirectly affecting the human host.

The fungal fraction of the microbiome, the mycobiome, is important in maintaining intestinal homeostasis and immunity. But although the field of mycobiome research has advanced, this omics technology is still in its infancy. Early studies have shown that Candida overgrowth can be linked to ALD and...

---

**Fig. 4.** Population-based vs. personalised omics biomarkers: Promises and challenges. miR, microRNA. Examples are based on references.
citrullinemia, and that elevated levels of anti-S. cerevisiae antibodies, which cross-react with Candida albicans, are associated with increased mortality in ALD.100–102

Proteomics

Proteins are the most prominent source of biomarkers and drug targets in human diseases. Routine laboratory testing is dominated by proteins (42% of all analytes) and, as of 2017, 75% of drugs approved by the US FDA target human proteins.28 Aminotransferases, albumin, bilirubin and coagulation factors are examples of proteins that are routinely measured to assess liver function.

Proteomics seeks to map all proteins in a biological sample, with existing platforms quantifying hundreds to tens of thousands of proteins, depending on the sample type. Several cell type–resolved human liver proteome maps have been published, establishing a robust reference for the abundance of over ten thousand proteins in human liver cells.103 Mass spectrometry (MS)-based proteomics and affinity-based proteomics are commonly used technologies for the large-scale study of proteins. MS-based proteomics is the most comprehensive approach and the gold standard for the quantitative profiling of proteins, post-translational modifications and protein–protein interactions.104 MS-based proteomics is an ideal approach for unbiased protein profiling across all organisms and sample types (Table 2). The targeted approach, also known as discovery proteomics, offers a global view of the proteome and is often used to uncover novel biomarkers. However, the lack of standardisation as well as its semi–quantitative nature is a significant hurdle for discovery proteomics – values obtained in a specific study can typically only be compared horizontally to other samples acquired within the same study. In contrast, targeted MS-based proteomics focuses on specific proteins of interest, providing precise quantification, validation and clinical applications.

Recent technological advances in MS-based proteomics, including the automation of sample preparation, improvements in liquid chromatography, as well as the development of novel MS acquisition methods and sophisticated informatics solutions, have made it feasible to generate thousands of proteome profiles in a single clinical study.105 This further translates into reproducible and robust results. At the same time, researchers have started to apply machine learning-based classification algorithms to demonstrate the predictive or discriminative power of proposed biomarkers in liver disease.

Affinity-based proteomics platforms, such as Olink and SomaScan, have been widely applied in human plasma and serum studies.45,106,107 These platforms offer measurements for dozens and up to thousands of proteins, with standardised workflows allowing for value comparison across studies. However, studies comparing the two platforms have highlighted inconsistencies in quantification for a significant number of proteins.106 Consequently, findings from these platforms often require validation by an orthogonal method, ideally mass spectrometry, which excels in its specificity of identification and quantification.109 Other methods include ELISA and similar techniques, which measure the concentration of a single protein, making them better suited for biomarker validation and implementation.

The FDA-approved OVA1 test for ovarian cancer serves as an example of a biomarker identified by MS-based proteomics but which was ultimately developed using immunoassays. The test consists of a panel of five proteins, four of which were first published in 2004. Five years later the test received FDA clearance.110

More than 200 candidate protein biomarkers have been reported for MASLD and 22 for ALD, although none have matured into clinical practice.15,111–113 The two most recent proteomics biomarker studies were selected from 2,201 candidate proteins for MASLD fibrosis and 1,235 candidates for ALD fibrosis, resulting in eight- and nine-protein biomarker panels.15,113 Complement component C7 was part of both panels, while the other proteins differed. Consequently, much work remains to be done in terms of evaluation of disease specificity and external validation of these signatures.

Metabolomics and lipidomics

The metabolome comprises all small molecules in the human body, originating from both endogenous and environmental sources, and encompasses a biochemically diverse array of metabolites such as sugars, lipids, amino acids, fatty acids, alkaloids, and polyphenols.114 One example of a lipid metabolite biomarker is phosphatidylethanol, used to detect alcohol consumption, derived from the trans-phosphatidylation of phosphatidylcholine in the presence of ethanol.115

Humans are thought to contain around 3,000 endogenous or common metabolites while the plant kingdom harbours around 200,000 metabolites, of which 90% are still unquantified or unidentified.114 Metabolomics platforms are usually a combination of different chemical analyses using mass spectrometry. The platforms detect anything between 100 and 1,000 metabolites, and their quality is based on prior work identifying the metabolites with pure standards in in-house identification libraries. Public libraries are available to characterise molecular features but they only provide putative identifications as the certainty is insufficient to derive meaningful conclusions. In addition, machine learning approaches are used to identify the large number of new metabolites.115 MS- and affinity-based metabolomics can detect several thousand human metabolites, although, as mentioned, the diverse nature of the metabolome necessitates the use of multiple analytical chemistry techniques (Table 2).114

Lipidomics is an especially promising metabolomics technique for biomarker discovery in steatotic liver disease. In a study of early ALD, the lipidomic signature of patients with ALD began to differ from matched healthy controls at the stage of minimal fibrosis.117 The bioactive lipid classes sphingomyelins and phosphocholines were downregulated in both liver tissue and plasma with increasing fibrosis stages and were both diagnostic of significant fibrosis and predictive of liver-related outcomes. This finding was validated in an independent cohort of patients with advanced ALD cirrhosis.118 Other studies suggest that lipid panels can predict advanced forms of MASLD: molecular lipids in blood have shown good diagnostic performance for MASLD and MASH (metabolic dysfunction–associated steatohepatitis) in well-powered studies, with elevated triglycerides and reduced lysophosphatidylcholines and phospholipids.119,120 Interestingly, unsaturated triglycerides are increased with the presence of the PNPLA3 risk
A 10-metabolite panel including eight eicosanoid molecules predicted advanced fibrosis with an area under the receiver-operating characteristic curve of 0.94. Finally, recent data suggest that the liver lipidome of patients with ALD responds differently to acute alcohol intoxication than that of patients with MASLD. This finding indicates that there are likely distinct molecular differences between the two diseases, which may explain the marked difference in disease progression and risk of liver-related complications.

The use of metabolomics and lipidomics in hepatology is challenged by specificity, as most known metabolites have common disease pathways. Furthermore, while some metabolites are found to be stable, others, such as glucose and cholesterol, have been shown to exhibit a daily flux or be affected by diet. Hence, the establishment of a baseline level is important, especially when measured longitudinally throughout liver disease progression or regression.

**Multi-omics**

Clinical studies are increasingly generating multiple omics layers, allowing for integrated multi-omics investigations of liver disease. Machine learning-based feature selection from several omics layers can help determine the diagnostic and prognostic weight of each omics layer, but more importantly, multi-omics integration can capture disease complexity by addressing biologically relevant interactions between genes, their expression and their products. Unfortunately, integrating multiple types of omics remains a computational barrier. Consequently, current multi-omics studies rarely integrate more than two omics layers, and often instead interpret the outputs in parallel.

One study of multi-omics integration performed GWAS in 9,491 patients with MASLD and detected 20 gene variants predictive of steatosis and/or cirrhosis. From this, the
researchers combined GWAS with transcriptomics and proteomics to derive expression quantitative trait loci and protein quantitative trait loci in the European population. This multiomics integration resulted in 16 putative genes associated with 273 circulating proteins, enriched in order to enable multiple metabolic and catabolic processes, including the metabolism of hormones, lipids, alcohol, vitamins, steroids and monocarboxylic acid. This represents an integrative step forward in understanding disease mechanisms.

The regulatory landscape from an omics perspective

The regulatory qualification of a biomarker requires thorough planning and patience. For example, the Enhanced Liver Fibrosis test (Siemens Healthcare) obtained FDA approval in 2021, with the first core clinical study published in 2004 (Fig. 5). For the nordicPRO-C3™ biomarker (pro-peptide of type III collagen, Nordic Bioscience and Roche Diagnostics), it took 5 years to complete assay development, minimising pre-analytical measurement uncertainty, followed by 6 years to create clinical evidence before having a Letter of Intent accepted by the FDA (Fig. 5).

Every year, thousands of papers on biomarkers are published, yet very few enter clinical practice. This so-called valley of death is the consequence of the failed transition from academic studies to implementation and commercialisation.

There are many reasons for the transition to fail. First, understanding the biological, pre-analytical and analytical factors that contribute to measurement uncertainty is important. Second, when validating a biomarker, the FDA mandates the establishment of a predefined hypothesis and statistical analysis plan. Hence, the distribution of the cohort needs to allow for sufficient statistical power to address the potential context of use, whether it is diagnostic, prognostic or predictive. The 2016 BEST (Biomarkers, Endpoints and Other Tools) resource from the FDA and National Institutes of Health Biomarker Work Group provides a notable glossary of biomarker definitions. These considerations are important in moving from discovery to the internal and external validation of a biomarker. Third, for a study to adhere to Good Clinical Practice, regulatory standards, protocols and documents need to be in place, describing procedures for sample collection and handling, measurement techniques and quality assurance systems. Fourth, biomarker measurements need to be conducted within certified laboratories and the informed consent process should encompass the explicit acceptance of sample utilisation for research, as well as for registration and commercialisation. To make a real difference, a biomarker needs to be implemented on a worldwide platform, and while many biomarkers may be interesting in a research setting, very few qualify according to the Clinical and Standards Institute guidelines.

The current failure of omics to transition from academic research to implementation and commercialisation may be partly due to the untargeted nature of most omics analyses, rendering them best suited for discovery. But the field also remains hampered by study designs dominated by retrospective studies that do not adhere to regulatory requirements. However, the burden is not only on biomarker research and development units, but also on regulatory agencies such as the FDA and the EMA, which have been slow to adapt their approval procedures to the large data generated by omics on novel measurement platforms, using advanced biostatistical methods. The Head of Medicines Agencies report on Big Data was only issued in 2019, along with a subgroup report on Bioanalytical Omics.

Conclusion

Omics technologies offer several advantages. They can identify associations between biomolecules and diseases, uncover underlying mechanisms and identify new biomarkers with untargeted hypothesis-free or targeted hypothesis-driven approaches. Despite the growing enthusiasm, we currently find ourselves in an exploratory phase where there is a lack of sufficient high-quality studies to provide the conclusive evidence of analytical validity, discovery, development and validation that would meet the requirements of regulatory authorities. The next 5 to 10 years should see crucial improvements in the evidence base and maturity of multi-omics, allowing for the first omics-based biomarkers to enter clinical practice as precision tools for personalised medicine.

Affiliations

1Center for Liver Research, Department of Gastroenterology and Hepatology, Odense University Hospital, Odense, Denmark; 2Department for Clinical Research, University of Southern Denmark, Odense, Denmark; 3Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; 4Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany; 5Steno Diabetes Center Copenhagen, Herlev, Denmark; 6Structural and Computational Biology Unit, European Molecular Biology Laboratory, Heidelberg, Germany; 7KU Leuven, Department of Microbiology, Immunology, and Transplantation, Rega Institute, Laboratory of Viral Metagenomics, Leuven, Belgium; 8Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Science, University of Copenhagen, Copenhagen, Denmark; 9Medizinische Klinik B (Gastroenterologie, Hepatologie, Endokrinologie, Klinische Infektiologie), Universitätshospital Münster Westfälische, Wilhelms-Universität Münster, Germany; 10Idryma Iatroviologikon Ereunon Akademias Athinon, Greece; 11Fibrosis, Hepatic and Pulmonary Research, Nordic Bioscience, Herlev, Denmark; 12Department of Science and Environment Roskilde University, Roskilde, Denmark; 13Max Delbrück Centre for Molecular Medicine, Berlin, Germany; 14Department of Bioinformatics, Biocenter, University of Würzburg, Würzburg, Germany

Abbreviations

ALD, alcohol-related liver disease; GCKR, glucokinase regulator; GPAM, glycerc-3-phosphate acyltransferase, mitochondrial; GRS, genetic risk scores; GWAS, genome-wide association studies; HSD17B13, hydroxysteroid 17-beta dehydrogenase 13; MASLD, metabolic dysfunction-associated steatotic liver disease; MAF, minor allele frequency; MBQT7, membrane bound O-acyltransferase domain-containing 7; MeALD, MASLD with increased alcohol intake; miRNA, microRNA; MS, mass spectrometry; MTAPC1, mitochondrial amidoxime reducing component 1; PNPLA3, patatin-like phospholipase domain-containing protein 3; PSD3, pleckstrin and Sec7 domain-containing 3; qPCR, quantitative PCR; SERPIN1, serpin family A member 1; SNPs, single nucleotide polymorphisms; TM6SF2, transmembrane 6 superfamily member 2.

Financial support

This project has received funding from the GALAXY project from the European Union’s Horizon 2020 research and innovation programme under grant agreement number 668031; and from Challenge Grant “MicrobLiver” grant number NNF15OC0016692 from the Novo Nordisk Foundation. LVE is funded by the Fonds Wetenschappelijk Onderzoek (FWO) Vlaanderen (grant number 1525720N). MT is funded by a grant from the Novo Nordisk Foundation.
Conflict of interest
MT: Speaker’s fee from Echosens, Siemens Healthcare, Norgine, Tillotts Pharma, and advisory fee from GE Healthcare. DJL and MK: Fulltime employee and stockholder of Nordic Bioscience. AK: Speaker for Novo Nordisk, Norgine, Siemens, and Nordic Bioscience and participated in advisory boards for Norgine, Siemens, Resalits Therapeutics, Boehringer Ingelheim and Novo Nordisk, all outside the submitted work. Research support: Norgine, Siemens, Nordic Bioscience, Astra, Echosens, Consulting Takeda, Resalits Therapeutics, Zealand Pharma, Novo Nordisk, Boehringer Ingelheim. Board member and co-founder Evido. JT: Speaker and/or consulting fees from Versantis, Gore, Boehringer-Ingelheim, Falk, Grifols, Genfit and CSL Behring. LJJ: Speaker’s fee from Boehringer Ingelheim Fonds.

Supplementary data
Please refer to the accompanying ICMJE disclosure forms for further details.

Authors’ contributions
Conceptualization: MT, IFV, SJ, LN, AK, TH. Writing – original draft: MT, IFV, LN, LJJ, SN, SJ, DJL, HBJ, AZ, KS, TS, MJB, MK, MKu, CCQ, SES, VH, LVE, MCAS, LTD. Visualisation: MT, IFV, SJ, LN, KS, CLQ, LJJ. Funding acquisition: TH, AK, PB, MT, MK, JM, MA, CLQ, MM, EA, JT. Writing – review and editing: all authors. All authors approved the final version of the manuscript.

Acknowledgements
We acknowledge Louise Skovborg Just and Lise Ryborg for their invaluable work in the GALAXY and MicrobLiver consortia. We also wish to acknowledge the researchers and managerial staff who have contributed to the GALAXY and MicrobLiver at various times during the project. For the creation of Figure 5, we would like to acknowledge the invaluable input received from Siemens Healthcare, William Rosenberg and Echosens.

Supplementary data
Supplementary data to this article can be found online at https://doi.org/10.1016/j.jhep.2024.03.035.

References
Author names in bold designate shared co-first authorship


